Novo Nordisk has filed CagriSema (cagrilintide + semaglutide) for chronic weight management. Resolves YES if the FDA grants approval on or before Dec 31, 2026. Source: FDA / Novo Nordisk.
Market open
Jun 15, 2026, 03:26 p.m.
Market closes
Jan 8, 2027, 02:26 p.m.
Projected payout
After market closes
